J. Favier, L. Amar, and A. Gimenez-roqueplo, Paraganglioma and phaeochromocytoma: from genetics to personalized medicine, Nature Reviews Endocrinology, vol.99, issue.2, pp.101-112, 2015.
DOI : 10.1073/pnas.75.9.4538

K. Janeway, S. Kim, M. Lodish, V. Nose, R. P. Gaal et al., Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations, Proceedings of the National Academy of Sciences, vol.108, issue.1, pp.314-322, 2011.
DOI : 10.1073/pnas.1009199108

O. Warburg, Ueber den stoffwechsel der tumoren. Constable, 1930.

I. Tomlinson, N. Alam, A. Rowan, E. Barclay, E. Jaeger et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4, pp.406-416, 2002.
DOI : 10.1038/ng849

H. Yan, D. Parsons, J. G. Mclendon, R. Rasheed, B. Yuan et al., Mutations in Gliomas, New England Journal of Medicine, vol.360, issue.8, pp.765-73, 2009.
DOI : 10.1056/NEJMoa0808710

A. Morin, E. Letouze, A. Gimenez-roqueplo, J. Favier, A. Gimenez-roqueplo et al., Oncometabolites-driven tumorigenesis: From genetics to targeted therapy Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. The Journal of clinical endocrinology and metabolism, Int J Cancer, vol.13598, issue.10, pp.2237-2285, 2013.

L. Amar, E. Baudin, N. Burnichon, S. Peyrard, S. Silvera et al., Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. The Journal of clinical endocrinology and metabolism Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas, Cancer Res, vol.9263, issue.12, pp.3822-85615, 2003.

E. Letouze, C. Martinelli, C. Loriot, N. Burnichon, N. Abermil et al., SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma, Cancer Cell, vol.23, issue.6, pp.739-52, 2013.
DOI : 10.1016/j.ccr.2013.04.018

A. Imperiale, F. Moussallieh, P. Roche, S. Battini, A. Cicek et al., Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications, Neoplasia, vol.17, issue.1, pp.55-65, 2015.
DOI : 10.1016/j.neo.2014.10.010

E. Korpershoek, J. Favier, J. Gaal, N. Burnichon, B. Van-gessel et al., Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9, pp.1472-1478, 2011.
DOI : 10.1210/jc.2011-1043

N. Lendvai, R. Pawlosky, P. Bullova, G. Eisenhofer, A. Patocs et al., Succinate-tofumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma, Endocrinology. J Clin Endocrinol Metab, vol.155100, issue.18, pp.27-32, 2014.

J. Rao, U. Engelke, R. Rodenburg, R. Wevers, K. Pacak et al., Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma, Clinical Cancer Research, vol.19, issue.14, pp.3787-95, 2013.
DOI : 10.1158/1078-0432.CCR-12-3922

J. Rao, U. Engelke, F. Sweep, K. Pacak, B. Kusters et al., Genotype-Specific Differences in the Tumor Metabolite Profile of Pheochromocytoma and Paraganglioma Using Untargeted and Targeted Metabolomics, The Journal of Clinical Endocrinology & Metabolism, vol.100, issue.2, pp.214-236, 2015.
DOI : 10.1210/jc.2014-2138

S. Richter, M. Peitzsch, E. Rapizzi, J. Lenders, N. Qin et al., Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis, J Clin Endocrinol Metab. Lancet Oncol, vol.9910, issue.22, pp.3903-11764, 2009.

P. Pollard, J. Briere, N. Alam, J. Barwell, E. Barclay et al., Accumulation of Krebs cycle intermediates and over-expression of HIF1?? in tumours which result from germline FH and SDH mutations, Human Molecular Genetics, vol.14, issue.15, pp.2231-2240, 2005.
DOI : 10.1093/hmg/ddi227

O. Andronesi, G. Kim, E. Gerstner, T. Batchelor, A. Tzika et al., Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy, Science Translational Medicine, vol.4, issue.116, pp.116-120, 2012.
DOI : 10.1126/scitranslmed.3002693

C. Choi, S. Ganji, R. Deberardinis, K. Hatanpaa, D. Rakheja et al., 2- hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas, Magnetic resonance lactate and lipid signals in rat brain after middle cerebral artery occlusion model, pp.624-9116, 2007.

N. Burnichon, L. Vescovo, L. Amar, R. Libe, A. De-reynies et al., Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma, Human Molecular Genetics, vol.20, issue.20, pp.3974-85, 2011.
DOI : 10.1093/hmg/ddr324

P. Webb, N. Sailasuta, S. Kohler, T. Raidy, R. Moats et al., Automated single-voxel proton MRS: Technical development and multisite verification, Magnetic Resonance in Medicine, vol.102, issue.4, pp.365-73, 1994.
DOI : 10.1002/mrm.1910310404

M. Agarwal, S. Chawla, N. Husain, R. Jaggi, M. Husain et al., Higher succinate than acetate levels differentiate cerebral degenerating cysticerci from anaerobic abscesses on in-vivo proton MR spectroscopy Biochemical and molecular investigations in respiratory chain deficiencies SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors al. Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics, Neuroradiology. Clin Chim Acta. Mod Pathol. Endocr Relat Cancer, vol.462282622, issue.33, pp.211-216, 1994.

S. Gonias, R. Goldsby, K. Matthay, R. Hawkins, D. Price et al., I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma, Journal of Clinical Oncology, vol.27, issue.25, pp.4162-4170, 2009.
DOI : 10.1200/JCO.2008.21.3496

C. Jimenez, E. Rohren, M. Habra, T. Rich, P. Jimenez et al., Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma, Current Oncology Reports, vol.41, issue.9, pp.356-71, 2013.
DOI : 10.1007/s11912-013-0320-x

J. Hadoux, J. Favier, J. Scoazec, S. Leboulleux, A. Ghuzlan et al., mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma, International Journal of Cancer, vol.118, issue.Suppl 2, pp.2711-2731, 2014.
DOI : 10.1002/ijc.28913

P. Xekouki, E. Szarek, P. Bullova, A. Giubellino, M. Quezado et al., Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in human and mice. The Journal of clinical endocrinology and metabolism In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma, Surgery, 2015.